Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Post-autologous transplant maintenance therapies in lymphoma: current state and future directions

Bone Marrow Transplantation volume 53, pages 11–21 (2018)Cite this article

Subjects

Abstract

Disease relapse following high-dose chemotherapy and autologous stem cell transplant (ASCT) remains the principal cause of mortality in patients with relapsed or refractory lymphomas. In an effort to prevent post-ASCT relapse, a number of studies have evaluated the role of maintenance therapy with varying success. In diffuse large B-cell lymphoma, studies evaluating maintenance rituximab (MR) following ASCT failed to demonstrate improved outcomes. In follicular lymphoma, MR was associated with an improvement in PFS; however, no overall survival (OS) benefit was noted. Emerging data evaluating MR in mantle cell lymphoma (MCL) have demonstrated improvements in PFS, although a consistent improvement in OS has yet to be demonstrated. Given the aggressive and incurable nature of MCL, it is prudent for practitioners to weigh the risks and benefits of MR in the post-ASCT setting. Similarly, post-ASCT maintenance therapy with brentuximab vedotin in Hodgkin lymphoma, has led to improved PFS and may be considered in those with a high risk of relapse. Ongoing clinical studies evaluating a multitude of novel maintenance therapies are crucial to the efforts of further defining and optimizing the role of post-transplant maintenance therapy in lymphoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  2. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054.

    Article  CAS  PubMed  Google Scholar 

  3. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359: 2065–2071.

    Article  CAS  PubMed  Google Scholar 

  4. Lancet JE, Rapoport AP, Brasacchio R, Eberly S, Raubertas RF, Linder T et al. Autotransplantation for relapsed or refractory Hodgkin’s disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1998; 22: 265–271.

    Article  CAS  PubMed  Google Scholar 

  5. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999; 17: 3101–3109.

    Article  CAS  PubMed  Google Scholar 

  6. Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000; 96: 2399–2404.

    CAS  PubMed  Google Scholar 

  7. Rapoport AP, Lifton R, Constine LS, Duerst RE, Abboud CN, Liesveld JL et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1997; 19: 883–890.

    Article  CAS  PubMed  Google Scholar 

  8. Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142–2148.

    CAS  PubMed  Google Scholar 

  9. Hamadani M . Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? Bone Marrow Transplant 2013; 48: 1013–1021.

    Article  CAS  PubMed  Google Scholar 

  10. Zhang W, Jiao L, Zhou DB, Shen T . Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Oncol Lett 2010; 1: 733–738.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tsirigotis P, Dray L, Resnick IB, Ackerstein A, Gesundheit B, Elad S et al. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin’s lymphoma. Ann Hematol 2010; 89: 263–272.

    Article  CAS  PubMed  Google Scholar 

  12. Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol 2009; 20: 1985–1992.

    Article  CAS  PubMed  Google Scholar 

  13. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30: 4462–4469.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE . Cd4+ T-cell immune response to large B-cell non-Hodgkin’s lymphoma predicts patient outcome. J Clin Oncol 2001; 19: 720–726.

    Article  CAS  PubMed  Google Scholar 

  15. Porrata LF, Litzow MR, Markovic SN . Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc 2001; 76: 407–412.

    Article  CAS  PubMed  Google Scholar 

  16. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013; 31: 4199–4206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Armitage JO, Weisenburger DD . New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795.

    Article  CAS  PubMed  Google Scholar 

  18. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42–51.

    Article  CAS  PubMed  Google Scholar 

  19. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28: 2853–2858.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Brugger W, Hirsch J, Grunebach F, Repp R, Brossart P, Vogel W et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004; 15: 1691–1698.

    Article  CAS  PubMed  Google Scholar 

  21. Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009; 43: 701–708.

    Article  CAS  PubMed  Google Scholar 

  22. Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2013; 31: 1624–1630.

    Article  CAS  PubMed  Google Scholar 

  23. Rajabi B, Sweetenham JW . Mantle cell lymphoma: observation to transplantation. Ther Adv Hematol 2015; 6: 37–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. McKay P, Leach M, Jackson R, Cook G, Rule S, British Committee for Standards in Haematology. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol 2012; 159: 405–426.

    Article  CAS  PubMed  Google Scholar 

  25. Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008; 113: 791–798.

    Article  PubMed  Google Scholar 

  26. Eskelund CW, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol 2016; 175: 410–418.

    Article  CAS  PubMed  Google Scholar 

  27. Dietrich S, Tielesch B, Rieger M, Nickelsen M, Pott C, Witzens-Harig M et al. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer 2011; 117: 1901–1910.

    Article  PubMed  Google Scholar 

  28. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 2013; 121: 48–53.

    Article  CAS  PubMed  Google Scholar 

  30. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520–531.

    Article  CAS  PubMed  Google Scholar 

  31. Dietrich S, Weidle J, Rieger M, Meissner J, Radujkovic A, Ho AD et al. Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma. Leukemia 2014; 28: 708–709.

    Article  CAS  PubMed  Google Scholar 

  32. Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR et al. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 2015; 26: 2323–2328.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Gyan E et al Rituximab Maintenance After Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. 2016 ASH Annual Meeting; 3–6 December 2016; San Diego, CA, 2016, Abstract 145.

  34. Kaplan LD, Jung SH, Stock W, Bartlett NL, Pitcher B, Byrd JC et al Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. 2015 ASH Annual Meeting; 5–8 December 2015; Orlando, FL, 2015, Abstract 337.

  35. Andersen NS, Donovan JW, Zuckerman A, Pedersen L, Geisler C, Gribben JG . Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. Exp Hematol 2002; 30: 703–710.

    Article  CAS  PubMed  Google Scholar 

  36. Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006; 107: 2271–2278.

    Article  CAS  PubMed  Google Scholar 

  37. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009; 27: 4365–4370.

    Article  CAS  PubMed  Google Scholar 

  38. Hasenclever D, Diehl V . A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998; 339: 1506–1514.

    Article  CAS  PubMed  Google Scholar 

  39. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 2005; 16: 625–633.

    Article  CAS  PubMed  Google Scholar 

  40. Martinez C, Canals C, Alessandrino E, Karakasis D, Leone G, Trneny M et al. Relapse of Hodgkin’s lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT. J Clin Oncol 2010; 28: 8060–8060.

    Article  Google Scholar 

  41. Nagler A, Berger R, Ackerstein A, Czyz JA, Diez-Martin JL, Naparstek E et al. A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation. J Immunother 2010; 33: 326–333.

    Article  CAS  PubMed  Google Scholar 

  42. Bosly A, Grigg A, Holte H, Gisselbrecht C, Radford J, Rossi A et al. A randomized study of interferon alpha-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma. Oncologist 2013; 18: 1189.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, Zhang J et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2012; 119: 4017–4025.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Oki Y, Buglio D, Zhang J, Ying Y, Zhou S, Sureda A et al. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer J 2014; 4: e236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012; 30: 2197–2203.

    Article  CAS  PubMed  Google Scholar 

  46. von Tresckow B, Skotnicki A, Lisukov I, Srivastava S, Morgan DS, Morschhauser F et al. A phase III randomized, double blind, placebo controlled multi-center study of panobinostat for maintenance of response in patients with hodgkin lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Blood 2013; 122: 4648.

    Google Scholar 

  47. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL . Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate (vol 16, pg 888, 2010). Clin Cancer Res 2011; 17: 5524.

    Article  Google Scholar 

  48. Younes A, Ansell SM . Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results. Semin Hematol 2016; 53: 186–189.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012; 30: 2183–2189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853–1862.

    Article  CAS  PubMed  Google Scholar 

  51. Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q et al. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 2011; 35: 380–386.

    Article  CAS  PubMed  Google Scholar 

  52. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952–4957.

    Article  PubMed  Google Scholar 

  53. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol 2011; 22: 1622–1627.

    Article  CAS  PubMed  Google Scholar 

  54. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 117: 5058–5066.

    Article  CAS  PubMed  Google Scholar 

  55. Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 2014; 15: 730–737.

    Article  CAS  PubMed  Google Scholar 

  56. Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol 2015; 33: 251–257.

    Article  CAS  PubMed  Google Scholar 

  57. Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2017; 35: 2473–2481 Jco2017726984.

    Article  CAS  PubMed  Google Scholar 

  58. Dean R, Pohlman B, Rybicki L, Maggiotto AL, Bates J, Smith SD et al Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma is Associated with Unacceptable Myelotoxicity. 2011 ASH Annual Meeting; 10–13 December 2011; San Diego, CA, 2011, Abstract 145.

  59. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol 2009; 27: 5404–5409.

    Article  CAS  PubMed  Google Scholar 

  60. Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688–3695.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716–723.

    Article  PubMed  CAS  Google Scholar 

  62. Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Eng J Med 2015; 373: 1835–1844.

    Article  CAS  Google Scholar 

  63. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118: 5119–5125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Fowler N, Davis E . Targeting B-cell receptor signaling: changing the paradigm. Hematol Am Soc Hematol Educ Program 2013; 2013: 553–560.

    Article  Google Scholar 

  65. Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM . B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol 2015; 52: 77–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Wilson WH, Gerecitano JF, Goy A, de Vos S, Kenkre VP, Barr PM et al. The bruton’s tyrosine kinase (BTK) inhibitor, Ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 2012; 120: 686.

    Google Scholar 

  67. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113: 6069–6076.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 690–697.

    Article  CAS  PubMed  Google Scholar 

  70. Davies AJ, Caddy J, Maishman T, Barrans S, Mamot C, Care M et al A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based Upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425). 2015 ASH Annual Meeting; 5–8 December 2015; Orlando, FL, 2015,Abstract 812.

  71. Offner F, Samoilova O, Osmanov E, Eom HS, Topp MS, Raposo J et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood 2015; 126: 1893–1901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Leonard JP, Kolibaba K, Reeves JA, Tulpule A, Flinn IW, Kolevska T et al Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918). 2015 ASH Annual Meeting; 5–8 December 2015; Orlando, FL, 2015, Abstract 811.

  73. Paoluzzi L, O'Connor OA . Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs 2006; 20: 13–23.

    Article  CAS  PubMed  Google Scholar 

  74. Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdallah R, Delarue R et al. Final results of a randomized phase 2 multicenter study of two bortezomib schedules in patients with recurrent or refractory follicular lymphoma. Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study FL–05. Blood 2010; 116: 768.

    Google Scholar 

  75. de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009; 27: 5023–5030.

    Article  CAS  PubMed  Google Scholar 

  76. Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011; 12: 773–784.

    Article  CAS  PubMed  Google Scholar 

  77. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867–4874.

    Article  PubMed  Google Scholar 

  78. Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015; 372: 944–953.

    Article  CAS  PubMed  Google Scholar 

  79. Chang JE, Li H, Smith MR, Gascoyne RD, Paietta EM, Yang DT et al. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood 2014; 123: 1665–1673.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117: 2807–2812.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462–3473.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM . Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res 2011; 17: 4232–4244.

    Article  CAS  PubMed  Google Scholar 

  83. Armand P . Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125: 3393–3400.

    Article  CAS  PubMed  Google Scholar 

  84. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311–319.

    Article  CAS  PubMed  Google Scholar 

  85. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016; 34: 3733–3739.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Proud CG . The multifaceted role of mTOR in cellular stress responses. DNA Repair (Amst) 2004; 3: 927–934.

    Article  CAS  Google Scholar 

  87. Vivanco I, Sawyers CL . The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489–501.

    Article  CAS  PubMed  Google Scholar 

  88. Pfeifer M, Lenz G . PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma. Cell Cycle 2013; 12: 3347–3348.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 2006; 134: 475–484.

    Article  CAS  PubMed  Google Scholar 

  90. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006; 108: 4178–4186.

    Article  CAS  PubMed  Google Scholar 

  91. Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A et al. Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: The University of Chicago Phase II Consortium. J Clin Oncol 2010; 28: 4740–4746.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011; 25: 341–347.

    Article  CAS  PubMed  Google Scholar 

  93. Frost P, Shi Y, Hoang B, Gera J, Lichtenstein A . Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Mol Cancer Ther 2009; 8: 83–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004; 279: 2737–2746.

    Article  CAS  PubMed  Google Scholar 

  95. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP . Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007; 21: 333–339.

    Article  CAS  PubMed  Google Scholar 

  96. Wang L, Shi WY, Wu ZY, Varna M, Wang AH, Zhou L et al. Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J Hematol Oncol 2010; 3: 30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822–3829.

    Article  CAS  PubMed  Google Scholar 

  98. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A . Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006; 132: 503–511.

    CAS  PubMed  Google Scholar 

  99. Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG . Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005; 205: 498–506.

    Article  CAS  PubMed  Google Scholar 

  100. Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K, Mathas S et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005; 106: 1801–1807.

    Article  CAS  PubMed  Google Scholar 

  101. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85: 320–324.

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Lim SH, Levy R . Translational medicine in action: anti-CD20 therapy in lymphoma. J Immunol 2014; 193: 1519–1524.

    Article  CAS  PubMed  Google Scholar 

  103. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101–1110.

    Article  CAS  PubMed  Google Scholar 

  104. Dai H, Wang Y, Lu X, Han W . Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst 2016; 108: pii: djv439.

  105. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33: 540–549.

    Article  CAS  PubMed  Google Scholar 

  106. Wang C, Wu Z, Wang Y, Guo Y, Dai H, Wang XH et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin’s lymphoma: an open-label phase I trial. Clin Cancer Res 2016; 23: 1156–1166.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA

    P A Riedell & M R Bishop

Authors
  1. P A Riedell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M R Bishop
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M R Bishop.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Riedell, P., Bishop, M. Post-autologous transplant maintenance therapies in lymphoma: current state and future directions. Bone Marrow Transplant 53, 11–21 (2018). https://doi.org/10.1038/bmt.2017.196

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.196

This article is cited by

Search

Advanced search

Quick links